contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nightingale-applies-for-its-shares-to-be-listed-on-the-main-market-of-nasdaq-helsinki

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Head of Nordic ER Development, Analyst

Antti Luiro

Nightingale Health operates in medical technology. The company specializes in the development of medical devices. The product portfolio is broad and includes platforms and services in blood tests that are used for disease prevention purposes. In addition to the main business, service and associated ancillary services are also offered. The business is run globally with the largest presence in Europe.

Nightingale Health

The submission of the application for moving to the main list was expected, as the company announced in November that it was looking into it. 

Translation: Original published in Finnish on 03/12/2025 at 06:34 pm EET
<a href="https://www.inderes.se/releases/nightingale-health-plc-applies-for-its-series-b-shares-to-be-listed-on-the-main-market-of-nasdaq-helsinki" target="_blank" rel="noopener">The submission of the application </a>for moving to the main list was expected, as the company announced in November that it was looking into it. Trading in Nightingale&apos;s B shares is expected to commence on the Main Market of Nasdaq Helsinki on Wednesday next week, March 19, and at the same time the shares will be removed from the First North Growth Market Finland marketplace. Nightingale is also still investigating the OTC trading of its shares in the US, and we consider it quite likely that after the main list transfer, the company will apply for an OTC listing later in the spring.
The changes are driven by the internationalization of the company&#x2019;s business. Nightingale has entered into a wide range of international partnerships, many of which have been in the US, so we do not think it is far-fetched to expect investor interest in the US market. In principle, a transfer to the main list and trading on the OTC market would facilitate international investments in the company.
The news has no impact on our view of the stock and we commented more extensively on this earlier in November&#xa0;<a href="https://www.inderes.se/analyst-comments/nightingale-explores-transfer-to-nasdaq-helsinki-main-list-and-otc-trading-in-the-us" target="_blank" rel="noopener">here.</a>

Inderes

Nightingale applies for its shares to be listed on the Main Market of Nasdaq Helsinki

	2024	25e	26e
Revenue	4.4	5.2	8.2
growth-%	4.2 %	19.2 %	58.2 %
EBIT (adj.)	-18.6	-17.3	-16.2
EBIT-% (adj.)	-426.6 %	-332.6 %	-197.1 %
EPS (adj.)	-0.29	-0.27	-0.25
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	-	-	-
EV/EBITDA	-	-	-

Nightingale Health

Key Estimate Figures07.03